| 心肌代谢药物治疗缺血性心脏病的研究进展 |
| |
| 引用本文： | 汤建民,黄振文. 心肌代谢药物治疗缺血性心脏病的研究进展[J]. 心血管病学进展, 2006, 27(3): 336-339 |
| |
| 作者姓名： | 汤建民 黄振文 |
| |
| 作者单位： | 1. 郑州大学第二附属医院心血管内科,河南,郑州,450014
2. 郑州大学第一附属医院心血管内科,河南,郑州,450052 |
| |
| 摘 要： | 近年来通过改变心肌代谢发挥抗心绞痛作用的一类药物受到关注。这类代谢药物主要通过诱导游离脂肪酸代谢向葡萄糖代谢的转换,从而增加单位氧耗生成三磷酸腺苷供能物质的量而发挥抗心绞痛作用。适用于冠心病、肥厚型心肌病、非手术主动脉狭窄和慢性心力衰竭心肌缺血的治疗。代谢药物有可能成为缺血性心脏病患者药物治疗新的选择。现对4种心肌代谢药物进行综述。
|
| 关 键 词： | 代谢 冠心病 心绞痛 心肌缺血 |
| 文章编号： | 1004-3934(2006)03-0336-04 |
| 收稿时间： | 2005-08-22 |
| 修稿时间： | 2005-08-22 |
Treatment of Ischemic Heart Disease with Myocardial Metabolic Agents |
| |
| TANG Jian-min,HUANG Zhen-wen. Treatment of Ischemic Heart Disease with Myocardial Metabolic Agents[J]. Advances in Cardiovascular Diseases, 2006, 27(3): 336-339 |
| |
| Authors: | TANG Jian-min HUANG Zhen-wen |
| |
| Affiliation: | 1. Department of Cardiology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China ; 2. Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China |
| |
| Abstract: | It has recently been shown that antianginal drugs exert their anti-ischemic effects primarily by altering myocardial metabolism. These metabolic drugs induce a shift from free fatty acid towards predominantly glucose utilisation by the myocardium to increase ATP generation per unit of oxygen consumption. The drugs are used to treat ischemia due to coronary heart disease, hypertrophic cardiomyopathy, inoperable aortic stenosis, and chronic heart failure. Metabolic drugs may be a new option for treating ischemic heart disease. Four metabolic drugs are reviewed: perhexilline, trimetazidine, ranolazine, and etomoxir. |
| |
| Keywords: | metabolism coronary heart disease angina myocardial ischemia |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
